CIPLA Cipla Q2 FY26 results (Jul–Sep 2025) and concall
Cipla delivered exceptional Q2 FY26 performance with record quarterly revenue driven by growth across all priority markets - One India, US Generics, One Africa and EMEU. The quarter was marked by strategic milestones including the tirzepatide partnership with Eli Lilly and leadership succession planning with Achin Gupta's appointment as designated CEO.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 4,971 | 4,798 | 5,046 | 5,226 |
| EBITDA | 1,662 | 1,319 | 1,624 | 1,523 |
| Net profit | 1,438 | 1,485 | 1,303 | 1,211 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
